Thiazide Diuretics as First‑Line Treatment for Hypertension in Patients with Coronary Artery Disease and Prior Stroke

Guideline Recommendations

The 2024 European Society of Cardiology (ESC) guidelines designate thiazide or thiazide‑like diuretics as Class I, Level A first‑line agents for hypertension, including patients with established cardiovascular disease such as CAD and prior cerebrovascular accident. 1
The American Heart Association (AHA) recommends that patients with hypertension and chronic stable angina receive a regimen that includes a thiazide diuretic (Class I, Level A). [2][3]
The World Stroke Organization advises that, for secondary stroke prevention, an angiotensin‑converting enzyme inhibitor combined with a thiazide diuretic should be used to lower recurrence risk in both ischemic stroke and TIA patients. 4

In adults with atherosclerotic disease, a triple regimen of a β‑blocker, an ACE inhibitor or ARB, and a thiazide diuretic is recommended even when there is no prior myocardial infarction, diabetes, or left‑ventricular systolic dysfunction (Class IIa, Level B). [2][3]

For patients with established cardiovascular disease (including prior MI or stroke), the target blood pressure is < 130/80 mm Hg. [1][4]
The 2024 ESC guidelines further specify a systolic target of 120–129 mm Hg for all adults, provided the goal is tolerated (Class I, Level A). 1
In CAD patients, blood‑pressure reduction should be gradual, avoiding a diastolic pressure < 60 mm Hg because this may precipitate myocardial ischemia. [2][3]

Initial monitoring: check serum electrolytes (sodium, potassium) and renal function (eGFR, creatinine) 2–4 weeks after starting or uptitrating a thiazide. [5][7]
Ongoing surveillance: once target blood pressure is achieved, repeat electrolyte and renal‑function tests every 3–6 months in stable patients without additional risk factors. [5][7]
Orthostatic assessment: measure supine and standing blood pressure to detect orthostatic hypotension, especially in elderly patients and those with prior stroke. 5

Hypokalemia associated with thiazides can trigger life‑threatening arrhythmias and sudden death, particularly in heart‑failure patients or those on QT‑prolonging drugs. 5
Hyponatremia risk is markedly higher in elderly women taking HCTZ. 5
Patients should hold or reduce thiazide doses during acute illnesses with vomiting, diarrhea, or reduced oral intake to prevent severe hyponatremia. 5

Thiazides are contraindicated in individuals with eGFR < 30 mL/min/1.73 m², severe hyponatremia, systolic blood pressure < 90 mm Hg, or severe metabolic acidosis. 5
When GFR falls below 30 mL/min/1.73 m², thiazides become ineffective and should be replaced with loop diuretics. 5

Avoid concurrent ACE inhibitor + ARB therapy because it raises the risk of hyperkalemia and acute kidney injury without added cardiovascular benefit. 6
When HCTZ is combined with ACE inhibitors, ARBs, or aldosterone antagonists, potassium monitoring is essential due to opposing effects on potassium balance. 7
Initiating an ACE inhibitor or ARB together with HCTZ may increase the risk of hypotension; staggered initiation is advisable. 5

Hyperuricemia is a common metabolic side effect of HCTZ therapy. 5
In patients with diabetes, thiazides may induce hyperglycemia, necessitating adjustment of antidiabetic medications. 7
HCTZ can cause hypovolemia and dehydration; regular assessment of volume status (weight, physical exam) is recommended. 5
Elderly patients are more prone to orthostatic hypotension, renal function decline, and electrolyte disturbances when using thiazides. 5